Extrathymic malignancy in patients with myasthenia gravis

Area of Science:

• Neurology
• Oncology
• Immunology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Thymectomy is a common treatment for MG.
• The association between MG, thymoma, and extrathymic malignancies requires further investigation.

Purpose of the Study:

• To investigate the incidence of extrathymic malignancies in patients who underwent thymectomy for myasthenia gravis.
• To determine if there is a higher prevalence of extrathymic malignancies in thymomatous MG compared to non-thymomatous MG.

Main Methods:

• Retrospective analysis of 296 patients with myasthenia gravis who underwent thymectomy.
• Review of medical literature to compile cases of MG with extrathymic malignancies.
• Statistical comparison of extrathymic malignancy rates between thymomatous and non-thymomatous MG.

Main Results:

• Extrathymic malignancies were identified in 5 out of 296 (1.7%) thymectomized MG patients.
• Four of the five cases with extrathymic malignancies had thymomatous MG.
• Extrathymic malignancies occurred more frequently in thymomatous MG (4/5) than in non-thymomatous MG.
• Literature review identified 59 additional cases, totaling 60 extrathymic malignancies in MG patients.
• Leukemia and reticulo-endothelial sarcoma were the most common types of extrathymic malignancies observed.

Conclusions:

• Patients with thymomatous myasthenia gravis have an increased risk of developing extrathymic malignancies.
• Leukemia and reticulo-endothelial sarcoma are significant extrathymic malignancies associated with myasthenia gravis.